Cancers | Free Full-Text | Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer | HTML
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
PACIFIC Trial Leads to Durvalumab Approval in United States - ILCN.org (ILCN/WCLC)
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer - Lung Cancer
AstraZeneca presents superior progression-free survival for IMFINZI® ( durvalumab) in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress
First-line Durvalumab Improves Survival
Stage III NSCLC - NSCLC Treatment Paradigm - Text Module - NSCLC Practical Guidance - Oncology - Clinical Care Options
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
PACIFIC phase III trial scheme. | Download Scientific Diagram
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - ScienceDirect
First-line Durvalumab Improves Survival
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis - Lung Cancer
PACIFIC 5-Yr Update - Capsule Summary Slidesets - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
david vicente baz on Twitter: "Very proud of our contribution to PACIFIC clinical trial. Durvalumab as new standard of care in unresectable stage III non small cell lung cancer after chemoradiotherapy Many
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study - Clinical Lung Cancer
Durvalumab - Wikipedia
Durvalumab in non-small-cell lung cancer patients: current developments | Future Oncology
PACIFIC: Durvalumab in Stage III NSCLC - Capsule Summary Slidesets - 2018 WCLC Annual Meeting - Oncology - Clinical Care Options
